Lecanemab for mild Alzheimer disease – is there a way forward?
This Editorial reviews data on the efficacy and adverse effects of lecanemab amongst individuals with mild Alzheimer disease. Additionally, the recent controversy regarding the rejection by the EMA of a marketing authorization request for lecanemab, followed by its subsequent approval, is also discu...
Saved in:
| Main Author: | Rajesh R Tampi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BioExcel Publishing Ltd
2025-03-01
|
| Series: | Drugs in Context |
| Subjects: | |
| Online Access: | https://www.drugsincontext.com/lecanemab-for-mild-alzheimer-disease-is-there-a-way-forward/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Amyloid solutions: lecanemab, gantenerumab, and donanemab in the treatment of Alzheimer's disease
by: Taha basit Ameen, et al.
Published: (2025-05-01) -
Alzheimer’s Disease in the Context of an Aging Society: Challenges and Future Directions
by: Aleksandra Boral, et al.
Published: (2025-07-01) -
Disease Modifying Monoclonal Antibodies and Symptomatic Pharmacological Treatment for Alzheimer’s Disease
by: Xiaoming Qi, et al.
Published: (2024-11-01) -
Monoclonal antibodies against beta-amyloid protein (lecanemab and donanemab) should not be used in the treatment of Alzheimer's disease
by: Ricardo Nitrini, et al.
Published: (2025-05-01) -
Second-generation anti-amyloid monoclonal antibodies for Alzheimer’s disease: current landscape and future perspectives
by: Byeong-Hyeon Kim, et al.
Published: (2025-01-01)